Maximum quantity allowed is 999
请选择数量
CAS RN: 61825-94-3 | 產品號碼: O0372
Oxaliplatin
×
| 包裝 | 價格 | 同一天 | 2-3个工作日 | 左側以上貨期 |
貨期資訊
|
|---|---|---|---|---|---|
| 100MG |
NT$10,305
|
10 | ≥40 | 下單後約2週內可以出貨 |
* 以上價格已含運費關稅等但一些需要海運以及乾冰運輸的產品除外,詳情請與
當地經銷商
洽詢。
* TCI會時常優化儲存條件,儲存溫度請以在線目錄為準，敬請留意。
| 產品號碼 | O0372 |
| 分子式 / 分子量 | C__8H__1__4N__2O__4Pt = 397.29 |
| 外觀與形狀（20°C） | Solid |
儲存條件 
|
Refrigerated (0-10°C) |
| 儲存在惰性氣體下 | Store under inert gas |
| 應避免的情況 | Moisture Sensitive,Heat Sensitive |
| 包裝和容器
|
100MG-Glass Bottle with Plastic Insert （閲覽圖片） |
| CAS RN | 61825-94-3 |
| Reaxys-RN | 14621501 |
| PubChem Substance ID | 125309438 |
| Merck Index(14) | 6912 |
| MDL編號 | MFCD00866327 |
產品規格
| Appearance | White to Almost white powder to crystal |
| Elemental analysis(Nitrogen) | 6.70 to 7.40 % |
| NMR | confirm to structure |
性質
GHS
| 圖形表示 |
|
| 信號詞 | Danger |
| 危險性說明 | H315 : Causes skin irritation. H319 : Causes serious eye irritation. H317 : May cause an allergic skin reaction. H334 : May cause allergy or asthma symptoms or breathing difficulties if inhaled. H341 : Suspected of causing genetic defects. |
| 防範說明 | P501 : Dispose of contents/ container to an approved waste disposal plant. P261 : Avoid breathing dust. P272 : Contaminated work clothing should not be allowed out of the workplace. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection. P284 : Wear respiratory protection. P302 + P352 : IF ON SKIN: Wash with plenty of water. P342 + P311 : If experiencing respiratory symptoms: Call a POISON CENTER/doctor. P308 + P313 : IF exposed or concerned: Get medical advice/ attention. P337 + P313 : If eye irritation persists: Get medical advice/ attention. P305 + P351 + P338 : IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P362 + P364 : Take off contaminated clothing and wash it before reuse. P304 + P340 : IF INHALED: Remove person to fresh air and keep comfortable for breathing. P333 + P313 : If skin irritation or rash occurs: Get medical advice/ attention. P405 : Store locked up. |
相關法規
| RTECS # | TP2275850 |
運輸資料
| HS編碼* | 2843.90-000 |
Application
Platinum Coordination Complexes as Antitumor Agents
The development of platinum coordination complexes as antitumor agents began in the 1960s, and the highest antitumor activity was exhibited by cisplatin [D3371], approved by FDA in 1978. Improved versions carboplatin [C2043] and oxaliplatin were developed to avoid the serious side effects and the problem with resistance associated with the use of cisplatin.1-5)
The platinum complexes diffuse to the tumor cell, where they undergo hydrolysis displacement of their one chloride or carboxylate group leading to a platinum cation. The resulting cation coordinates to the guanine N7-position of DNA give a coordination cation. Then, intrastrand cross-linking occurs to anther guanine via further hydrolysis displacement of the remaining chloride or carboxylate. The forming [Pt(NH2R)2]2+ ― DNA complex distort the DNA helix (Fig. 1 and 2)6). Thus, DNA duplication is hindered, which ultimately triggers tumor cell apoptosis.3)
The platinum complexes diffuse to the tumor cell, where they undergo hydrolysis displacement of their one chloride or carboxylate group leading to a platinum cation. The resulting cation coordinates to the guanine N7-position of DNA give a coordination cation. Then, intrastrand cross-linking occurs to anther guanine via further hydrolysis displacement of the remaining chloride or carboxylate. The forming [Pt(NH2R)2]2+ ― DNA complex distort the DNA helix (Fig. 1 and 2)6). Thus, DNA duplication is hindered, which ultimately triggers tumor cell apoptosis.3)
References
- 1)G. Mathe, Y. Kidani, M. Segiguchi, M. Eriguchi, G. Fredj, G. Peytavin, J. L. Misset, S. Brienza, F. de Vassals, E. Chenu, C. Bourut, Biomed. Pharmacother. 1989, 43, 237.
- 2)L. R. Kelland, S. Y. Sharp, C. F. O’Neill, F. I. Raynaud, P. J. Beale, I. R. Judson, J. Inorg. Biochem. 1999, 77, 111.
- 3)D. Wang, S. J. Lippard, Nat. Rev. Drug Discov. 2005, 4, 307.
- 4)S. Trzaska, Chem. Eng. News 2005, 83, 3.
- 5)L. P. Martin, T. C. Hamilton, R. J. Schilder, Clin. Cancer Res. 2008, 14, 1291.
- 6)A. Gelasco, S. J. Lippard, Biochemistry, 1998, 37, 9230.
Application
Reagent for pain model
References
- Behavioral and pharmacological description of oxaliplatin-induced painful neuropathy in rat
- Behavioral and immunohistological assessment of painful neuropathy induced by a single oxaliplatin injection in the rat
- Mexiletine reverses oxaliplatin-induced neuropathic pain in rats
- N. Egashira, S. Hirakawa, T. Kawashiri, T. Yano, H. Ikesue, R. Oishi, J. Pharmacol. Sci. 2010, 112, 473.
Application
Pharmacology study
References
- Cellular and molecular pharmacology of oxaliplatin
- E. Raymond, S. Faivre, S. Chaney, J. Woynarowski, E. Cvitkovic, Mol. Cancer Therapeutics 2002, 1, 227.
- Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA
- J. M. Woynarowski, W. G. Chapman, C. Napier, M. C. S. Herzig, P. Juniewicz, Mol. Pharmacol. 1998, 54, 770.
- Oxalato-platinum or l-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum
PubMed Literature
文檔
產品介紹報導
產品文件 （部分產品的分析圖譜無法提供，敬請諒解。）
請輸入TCI產品號碼
text.certificate.product.input.placeholder.kishida
4或5個單字節字母數字字符
text.certificate.lotno.input.placeholder.kishida
SDS
產品規格
沒有搜索到 產品規格。
如需更多幫助，請 聯繫我們 。
text.specification.search.errormsg.content.1.kishida
檢驗報告(CoA)及其他文檔
請輸入批號
輸入的批號不正確
text.certificate.analysis.pdf.lotNumber.errorMessage.alphanumeric.kishida
• 請確認您輸入的批號。
• 如果您輸入的信息無誤，請 聯繫我們 。
• text.certificate.analysis.pdf.errormsg.content6.kishida
示例 CoA
可下載CoA示例。注：該示例可能非最新批次的CoA。
目前沒有該產品的 CoA 示例。
分析圖譜
請輸入批號
輸入的批號不正確
text.certificate.analysis.pdf.lotNumber.errorMessage.alphanumeric.kishida
很抱歉，您搜索的分析圖譜無法提供。